AR053596A1 - Forma polimorfa ii de tanaproget - Google Patents

Forma polimorfa ii de tanaproget

Info

Publication number
AR053596A1
AR053596A1 ARP060101668A ARP060101668A AR053596A1 AR 053596 A1 AR053596 A1 AR 053596A1 AR P060101668 A ARP060101668 A AR P060101668A AR P060101668 A ARP060101668 A AR P060101668A AR 053596 A1 AR053596 A1 AR 053596A1
Authority
AR
Argentina
Prior art keywords
degree
tanaproget
polymorph
lacks
tanaproget polymorph
Prior art date
Application number
ARP060101668A
Other languages
English (en)
Spanish (es)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR053596A1 publication Critical patent/AR053596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
ARP060101668A 2005-04-28 2006-04-26 Forma polimorfa ii de tanaproget AR053596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67573705P 2005-04-28 2005-04-28

Publications (1)

Publication Number Publication Date
AR053596A1 true AR053596A1 (es) 2007-05-09

Family

ID=36954854

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101668A AR053596A1 (es) 2005-04-28 2006-04-26 Forma polimorfa ii de tanaproget

Country Status (11)

Country Link
US (4) US7759341B2 (cg-RX-API-DMAC7.html)
EP (1) EP1874763A2 (cg-RX-API-DMAC7.html)
JP (2) JP2008539258A (cg-RX-API-DMAC7.html)
CN (1) CN101166736B (cg-RX-API-DMAC7.html)
AR (1) AR053596A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006241125B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0610433A2 (cg-RX-API-DMAC7.html)
CA (1) CA2603807A1 (cg-RX-API-DMAC7.html)
MX (1) MX2007013469A (cg-RX-API-DMAC7.html)
TW (1) TW200716621A (cg-RX-API-DMAC7.html)
WO (1) WO2006116526A2 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
US7767668B2 (en) * 2005-04-28 2010-08-03 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
MX2007013469A (es) * 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
WO2006116596A2 (en) * 2005-04-28 2006-11-02 Wyeth Micronized tanaproget and compostions containing same
BRPI0610438A2 (pt) 2005-04-28 2012-10-23 Wyeth Corp composição farmacêutica, cápsula, conjunto farmacêutico, e, processo para preparar uma composição
MX2007015571A (es) 2005-06-09 2008-03-06 Wyeth Corp Composiciones de tanaproget que contienen etinilestradiol.
US20090170823A1 (en) * 2007-12-20 2009-07-02 Duramed Pharmaceuticals, Inc. Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception
US20110237605A1 (en) * 2010-03-26 2011-09-29 Eric Phillips Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
EP2877465A4 (en) 2012-07-25 2016-05-11 Sarcode Bioscience Inc LFA-1 HEMMER AND POLYMORPH THEREOF
PL2900669T3 (pl) 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
AU2014356583B2 (en) 2013-11-26 2019-02-28 F. Hoffmann-La Roche Ag New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl
CR20160418A (es) 2014-03-26 2016-11-07 Hoffmann La Roche Nuevos compuestos biciclicos de 7 eslabones
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
AU2016328437A1 (en) 2015-09-24 2018-01-25 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
WO2017050747A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
BR112018006080A2 (pt) 2015-09-24 2018-10-09 F. Hoffmann-La Roche Ag novos compostos bicíclicos como inibidores de dupla ação de atx/ca
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100732692B1 (ko) * 1999-05-04 2007-06-27 와이어쓰 프로게스테론 수용체 조절인자인 시클로티오카르바메이트유도체
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
EP1531824A4 (en) * 2002-06-25 2005-09-21 Wyeth Corp CYCLOTHIOCARBAMATE DERIVATIVES AS PR-MODULATORS AND THEIR USE IN THE TREATMENT OF SKIN DISEASES
AU2003247608A1 (en) * 2002-06-25 2004-01-06 Wyeth Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
US8399013B2 (en) * 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
BRPI0510260A (pt) 2004-04-27 2007-10-23 Wyeth Corp método para purificar um composto, e, kit farmacêutico
PA8631101A1 (es) 2004-04-27 2006-09-08 Wyeth Corp Proceso de acoplamiento para la generacion de derivados reactivos de pirrol-2-carbonitrilo n-sustituidos con contenido de boro para producir biarilos
AU2005272854B2 (en) * 2004-08-13 2012-04-26 Wyeth Tanaproget derivatives, metabolites, and uses thereof
BRPI0610438A2 (pt) 2005-04-28 2012-10-23 Wyeth Corp composição farmacêutica, cápsula, conjunto farmacêutico, e, processo para preparar uma composição
ES2431324T3 (es) 2005-04-28 2013-11-26 Wyeth Llc Forma purificada de tanaproget
WO2006116596A2 (en) 2005-04-28 2006-11-02 Wyeth Micronized tanaproget and compostions containing same
US7767668B2 (en) 2005-04-28 2010-08-03 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
MX2007013469A (es) 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
MX2007015571A (es) 2005-06-09 2008-03-06 Wyeth Corp Composiciones de tanaproget que contienen etinilestradiol.

Also Published As

Publication number Publication date
JP2014088385A (ja) 2014-05-15
US8114869B2 (en) 2012-02-14
WO2006116526A8 (en) 2007-08-16
US7968709B2 (en) 2011-06-28
AU2006241125B2 (en) 2012-07-05
US7759341B2 (en) 2010-07-20
WO2006116526A3 (en) 2007-06-28
CN101166736A (zh) 2008-04-23
US20060247235A1 (en) 2006-11-02
JP2008539258A (ja) 2008-11-13
US20100267715A1 (en) 2010-10-21
BRPI0610433A2 (pt) 2010-11-23
EP1874763A2 (en) 2008-01-09
US20120115858A1 (en) 2012-05-10
TW200716621A (en) 2007-05-01
WO2006116526A2 (en) 2006-11-02
US20110212953A1 (en) 2011-09-01
AU2006241125A1 (en) 2006-11-02
CN101166736B (zh) 2013-02-06
CA2603807A1 (en) 2006-11-02
MX2007013469A (es) 2008-01-22

Similar Documents

Publication Publication Date Title
TW200716621A (en) Polymorph form II of tanaproget
CY1110017T1 (el) Μικρονισμενη ταναπρογετη και συνθεσεις που περιεχουν αυτην
AR056328A1 (es) TANAPROGET MICRONIZADO, COMPOSICIONES Y MÉTODOS PARA SU PREPARACIoN
MXPA03011985A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
CN103080080B (zh) 6,7-二氢-5h-苯并[7]轮烯衍生物、其制备方法、包含其的药物制剂以及其用于制备药物的用途
CY1106610T1 (el) Μεθοδος για την προληψη ή την θεραπευτικη αντιμετωπιση καλοηθων γυναικολογικων διαταραχων
CO4810234A1 (es) Vacunas para el tratamiento de virus papiloma humano
JP2008539258A5 (cg-RX-API-DMAC7.html)
DK1175398T3 (da) Indolinderivater som progesteronantagonister
TW200731969A (en) Use of progesterone receptor modulators
RU2016119135A (ru) Производные пиразолопиримидона или пирролотриазона, способ их получения и их фармацевтические применения
ATE515493T1 (de) Mercaptophenylnaphthylmethan-derivate und deren herstellung
DK1874278T3 (da) Sammensætninger indeholdende mikroniseret tanaproget
NZ515353A (en) Cyclothiocarbamate derivatives as progesterone receptor modulators
CR9598A (es) Moduladores no esteroides de receptor de progesterona
MX2009009515A (es) Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona.
CN103421057A (zh) 康普瑞汀氨基糖缀合物、其制法及其医药用途
ES2128635T3 (es) Procedimiento para la obtencion de sulfanos de 2-cloro-6-nitrofenil-alquilo, y nuevos sulfanos de 2-cloro-6-nitrofenilalquilo.
CY1109919T1 (el) Παραγωγα της ινδολης που ειναι χρησιμα σα ρυθμιστες του υποδοχεα της προγεστερονης
ECSP056180A (es) Alquil-estra-1,3,5(10)-trienos 8beta-vinil-11beta-(omega-sustituidos)
ATE263164T1 (de) Bentzothiophene
AR053595A1 (es) Forma purificada de tanaproget
PA8772001A1 (es) "SÍNTESIS Y CARACTERIZACIÓN DE LLA FORMA III POLIMÓRFICA DE 4-(-2-(4,4-DIMETIL-2-OXOOXAZOLIDIN-3i)BENZONITRILO"
KR20130083921A (ko) 항암 활성을 갖는 벤즈아미드 유도체 및 이의 제조 방법 및 용도
AR036976A1 (es) Uso de derivados de acidos 4-biarilbutiricos sustituidos para fabricar medicamentos para el tratamiento de enfermedades cerebrales, sales de los mismos, y composicion farmaceutica que los comprenden

Legal Events

Date Code Title Description
FA Abandonment or withdrawal